Drugs / DINOPROST
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT01689311 | Mar 2009 → Aug 2011 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT01327118 Comparator | Sep → Dec 2010 | headache disorder | Danish Headache Center | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DINOPROST | ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗ |
| Known as | Lutalyse | ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗ |
| Known as | Pgf2.alpha. | ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗ |
| Known as | Pgf2a | ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗ |
| Known as | PGF2α | “PURPOSE: To compare the in vitro contractile responses to oxytocin, ergonovine, prostaglandin F2 alpha (PGF2α), and misoprostol in isolated myometrium from” PMID 24906304 ↗ Jun 2014 |
| Known as | Prosmon | ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗ |
| Known as | prostaglandin F2 alpha | “PURPOSE: To compare the in vitro contractile responses to oxytocin, ergonovine, prostaglandin F2 alpha (PGF2α), and misoprostol in isolated myometrium from” PMID 24906304 ↗ Jun 2014 |
| Known as | U-14,583 | ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗ |
| Action | Activate | “Prostanoid FP receptor agonist” CHEMBL815 ↗ |
| Modality | Small molecule | — CHEMBL815 ↗ |
| Route | Intravenous | “intravenous injection” NCT01327118 ↗ |
| Target | PTGFR | “Prostanoid FP receptor agonist” CHEMBL815 ↗ |